Across TCGA pan-cancer cohorts, POTEI mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POTEI data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POTEI mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated POTEI expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where POTEI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.823	1.000	.002	31	view →
HNSC	DFS	Median	III,IV	0.867	0.709	.024	4	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	3	view →
PDAC	DFS	Tertile	IV	0.203	0.752	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: POTEI tumor-vs-normal RNA expression · all POTEI data types